Albireo Pharma, Inc. (ALBO) Financial Statements (2024 and earlier)

Company Profile

Business Address 10 POST OFFICE SQUARE
BOSTON, MA 02109
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2022
MRQ
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 248,107,000251,272,000131,843,000163,885,00053,231,00029,931,000
Cash and cash equivalents 248,107,000251,272,000131,843,000163,885,00053,231,00029,931,000
Receivables 3,272,000  2,915,000726,000370,000
Inventory, net of allowances, customer advances and progress billings 194,000     
Inventory 194,000     
Prepaid expense 5,261,000     
Other current assets 12,096,000     
Other undisclosed current assets  10,593,0009,956,000850,0001,054,000560,000
Total current assets: 268,930,000261,865,000141,799,000167,650,00055,011,00030,861,000
Noncurrent Assets
Property, plant and equipment 668,000478,000597,000187,000178,00021,000
Intangible assets, net (including goodwill) 17,260,00017,260,00017,260,00017,260,00017,260,00018,260,000
Goodwill 17,260,00017,260,00017,260,00017,260,00017,260,00018,110,000
Intangible assets, net (excluding goodwill)      150,000
Other noncurrent assets 15,193,0006,004,0005,413,000369,000775,000518,000
Total noncurrent assets: 33,121,00023,742,00023,270,00017,816,00018,213,00018,799,000
TOTAL ASSETS: 302,051,000285,607,000165,069,000185,466,00073,224,00049,660,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 42,467,00024,334,00018,271,00012,517,0007,455,0008,520,000
Accounts payable 6,516,0005,283,0004,785,0004,352,0001,350,000972,000
Accrued liabilities 35,951,00019,051,00013,486,0008,165,0006,105,0007,548,000
Debt      3,075,000
Derivative instruments and hedges, liabilities      844,000
Other liabilities 2,880,000948,000653,000308,000474,000207,000
Other undisclosed current liabilities      62,000
Total current liabilities: 45,347,00025,282,00018,924,00012,825,0007,929,00012,708,000
Noncurrent Liabilities
Long-term debt and lease obligation 20,822,00013,184,0004,186,000   
Long-term debt, excluding current maturities 10,004,0009,621,000    
Liabilities, other than long-term debt, including: 10,960,0003,579,0004,270,00035,00042,000 
Other liabilities 10,960,0003,579,0004,270,000 42,000 
Operating lease, liability 10,818,0003,563,0004,186,000
Other undisclosed liabilities, other than long-term debt    35,000  
Other undisclosed noncurrent liabilities 49,314,00062,331,00044,528,00049,969,000  
Total noncurrent liabilities: 81,096,00079,094,00052,984,00050,004,00042,000 
Total liabilities: 126,443,000104,376,00071,908,00062,829,0007,971,00012,708,000
Equity
Equity, attributable to parent 175,608,000181,231,00093,161,000122,637,00065,253,00036,952,000
Common stock 193,000191,000127,000120,00089,00063,000
Treasury stock, value (230,000)     
Additional paid in capital 475,390,000456,472,000245,769,000214,694,000114,522,00061,338,000
Accumulated other comprehensive income (loss) 1,105,000(8,612,000)6,452,0004,293,0001,001,0001,496,000
Accumulated deficit (300,850,000)(266,820,000)(159,187,000)(96,470,000)(50,359,000)(25,945,000)
Total equity: 175,608,000181,231,00093,161,000122,637,00065,253,00036,952,000
TOTAL LIABILITIES AND EQUITY: 302,051,000285,607,000165,069,000185,466,00073,224,00049,660,000

Income Statement (P&L) (USD)

9/30/2022
TTM
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues 40,579,0008,308,0009,636,00012,740,0001,00011,364,000
Revenue, net1,00011,364,000
Cost of revenue (1,356,000)     
Gross profit: 39,223,0008,308,0009,636,00012,740,0001,00011,364,000
Operating expenses (162,708,000)(104,579,000)(70,748,000)(50,630,000)(24,578,000)(23,658,000)
Operating loss: (123,485,000)(96,271,000)(61,112,000)(37,890,000)(24,577,000)(12,294,000)
Nonoperating income (expense) (10,423,000)14,573,0003,691,000(3,363,000)335,000(2,675,000)
Gain (loss), foreign currency transaction, before tax (10,423,000)14,573,000(4,006,000)(4,631,000)  
Loss from continuing operations before equity method investments, income taxes: (133,908,000)(81,698,000)(57,421,000)(41,253,000)(24,242,000)(14,969,000)
Other undisclosed income (loss) from continuing operations before income taxes 99,878,000(25,935,000)(5,296,000)(4,838,000)40,000(1,319,000)
Loss from continuing operations before income taxes: (34,030,000)(107,633,000)(62,717,000)(46,091,000)(24,202,000)(16,288,000)
Income tax expense    (20,000)(212,000)(62,000)
Loss from continuing operations: (34,030,000)(107,633,000)(62,717,000)(46,111,000)(24,414,000)(16,350,000)
Loss before gain (loss) on sale of properties:(34,030,000)(107,633,000)(62,717,000)(46,111,000)(24,414,000)(16,350,000)
Net loss available to common stockholders, diluted: (34,030,000)(107,633,000)(62,717,000)(46,111,000)(24,414,000)(16,350,000)

Comprehensive Income (USD)

9/30/2022
TTM
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss: (34,030,000)(107,633,000)(62,717,000)(46,111,000)(24,414,000)(16,350,000)
Other comprehensive income (loss) 9,717,000(15,064,000)2,159,0003,292,000(495,000)692,000
Comprehensive loss, net of tax, attributable to parent: (24,313,000)(122,697,000)(60,558,000)(42,819,000)(24,909,000)(15,658,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: